FastBack Bio

Executive Summary

FastBack Bio is a Cambridge, MA-based biotechnology company founded in 2021, dedicated to developing novel gene therapy delivery technologies to address key challenges in the cell and gene therapy sector. The company aims to enable the treatment of a broad range of genetic diseases by overcoming limitations in vector tropism, immunogenicity, and manufacturing scalability. Operating in the high-growth gene therapy space, FastBack Bio leverages proprietary platforms to target previously undruggable tissues, potentially expanding the therapeutic reach of gene therapies. Though still in early stages, the company's focus on delivery innovation positions it as a potential player in the next wave of genetic medicine.

Upcoming Catalysts (preview)

• Q3 2026Series A financing round70% success
• Q4 2026Preclinical proof-of-concept data for lead program60% success
• Q1 2027Publication of platform technology in peer-reviewed journal80% success